nach oben

Annals of Surgical Oncology

Erschienen in:

01.04.2005 | Educational Review

RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis

verfasst von: E. Ramsay Camp, MD, Wenbiao Liu, MD, Fan Fan, BS, Anthony Yang, MD, Ray Somcio, BA, Lee M. Ellis, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Tyrosine kinase receptors mediate many critical cellular functions that contribute to tumor progression and metastasis and thus are potential targets for molecular-based cancer therapy. As has been found for many receptor tyrosine kinases, RON (recepteur d’origine nantais) and its ligand, macrophage-stimulating protein, have recently been implicated in the progression and metastasis of tumors. In in vitro experiments using colon and breast cancer cell lines, overexpression of RON led to increased invasion and migration of cancer cells and prevented apoptosis and anoikis. In addition, transgenic mice engineered to overexpress RON in the lung epithelium developed multiple pulmonary tumors, suggesting a role for RON in tumorigenesis. In human cancer specimens, increased RON expression has been demonstrated in colon, breast, ovarian, and lung tumors. Therefore, therapies designed to inhibit RON activation may hinder critical tumor survival mechanisms and play a role in the treatment of advanced disease.

Mendelsohn, J 2002Targeting the epidermal growth factor receptor for cancer therapyJ Clin Oncol201S13SPubMed

Baselga, J 2001The EGFR as a target for anticancer therapy—focus on cetuximabEur J Cancer37S1622PubMed

Chen, YQ, Zhou, YQ, Angeloni, D, et al. 2000Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell linesExp Cell Res26122938PubMed

Wang, MH, Wang, D, Chen, YQ 2003Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinaseCarcinogenesis241291300PubMed

Hughes, AL 2000Modes of evolution in the protease and kringle domains of the plasminogen-prothrombin familyMol Phylogenet Evol1446978PubMed

Ronsin, C, Muscatelli, F, Mattei, MG, Breathnach, R 1993A novel putative receptor protein tyrosine kinase of the met familyOncogene81195202PubMed

Angeloni, D, Danilkovitch-Miagkova, A, Miagkov, A, et al. 2004The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activationJ Biol Chem279372632PubMed

Comoglio, PM, Tamagnone, L, Boccaccio, C 1999Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growthExp Cell Res2538899PubMed

Muraoka, RS, Sun, WY, Colbert, MC, et al. 1999The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouseJ Clin Invest103127785CrossRefPubMed

10.

Waltz, SE, Eaton, L, Toney-Earley, K, et al. 2001Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responsesJ Clin Invest10856776PubMed

11.

Iwama, A, Wang, MH, Yamaguchi, N, et al. 1995Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating proteinBlood863394403PubMed

12.

Gaudino, G, Avantaggiato, V, Follenzi, A, et al. 1995The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissuesOncogene11262737PubMed

13.

Maggiora, P, Lorenzato, A, Fracchioli, S, et al. 2003The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasivenessExp Cell Res2883829PubMed

14.

Chen, Q, Seol, DW, Carr, B, Zarnegar, R 1997Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell linesHepatology265966PubMed

15.

Peace, BE, Hill, KJ, Degen, SJ, Waltz, SE 2003Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptorExp Cell Res28931725PubMed

16.

Bardella, C, Costa, B, Maggiora, P, et al. 2004Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repressionCancer Res64515461PubMed

17.

Rulli, K, Yugawa, T, Hanson, C, et al. 2004Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase stk when activated by interaction with the friend spleen focus-forming virus envelope glycoprotein or by point mutationJ Virol78457381PubMed

18.

Leonard, EJ, Skeel, AH 1979Enhancement of spreading, phagocytosis, chemotaxis by macrophage stimulating protein (MSP)Adv Exp Med Biol121B18194PubMed

19.

Leonard, EJ, Skeel, AH 1978Isolation of macrophage stimulating protein (MSP) from human serumExp Cell Res11411726PubMed

20.

Yoshimura, T, Yuhki, N, Wang, MH, et al. 1993Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3J Biol Chem268154618PubMed

21.

Leonard, EJ, Danilkovitch, A 2000Macrophage stimulating proteinAdv Cancer Res7713967PubMedCrossRef

22.

Skeel, A, Leonard, EJ 2001alpha 1-Antichymotrypsin is the human plasma inhibitor of macrophage ectoenzymes that cleave pro-macrophage stimulating proteinJ Biol Chem276219327PubMed

23.

Wang, MH, Zhou, YQ, Chen, YQ 2002Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activitiesScand J Immunol5654553PubMed

24.

Maggiora, P, Marchio, S, Stella, MC, et al. 1998Overexpression of the RON gene in human breast carcinomaOncogene16292733PubMed

25.

Danilkovitch, A, Skeel, A, Leonard, EJ 1999Macrophage stimulating protein-induced epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent mechanismExp Cell Res24857582PubMed

26.

Danilkovitch-Miagkova, A, Angeloni, D, Skeel, A, et al. 2000Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-SrcJ Biol Chem275147836PubMed

27.

Liu, D, Aguirre Ghiso, J, Estrada, Y, Ossowski, L 2002EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinomaCancer Cell144557PubMed

28.

Boerner, JL, Danielsen, A, Maihle, NJ 2003Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigmExp Cell Res28411121PubMed

29.

Moro, L, Dolce, L, Cabodi, S, et al. 2002Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosinesJ Biol Chem277940514PubMed

30.

Gotzmann, J, Mikula, M, Eger, A, et al. 2004Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasisMutat Res566920PubMed

31.

Hsu, MY, Wheelock, MJ, Johnson, KR, Herlyn, M 1996Shifts in cadherin profiles between human normal melanocytes and melanomasJ Investig Dermatol Symp Proc118894PubMed

32.

Birchmeier, W, Behrens, J 1994Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasivenessBiochim Biophys Acta11981126PubMed

33.

Scheumman, GF, Hoang-Vu, C, Cetin, Y, et al. 1995Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomasJ Clin Endocrinol Metab80216872PubMed

34.

Wang, D, Shen, Q, Chen, YQ, Wang, MH 2004Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinaseOncogene23166880PubMed

35.

Danilkovitch, A, Donley, S, Skeel, A, Leonard, EJ 2000Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cellsMol Cell Biol20221827PubMed

36.

Danilkovitch-Miagkova, A, Leonard, EJ 2001Anti-apoptotic action of macrophage stimulating protein (MSP)Apoptosis618390PubMed

37.

Chen, YQ, Zhou, YQ, Fisher, JH, Wang, MH 2002Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivoOncogene2163826PubMed

38.

Peace, BE, Hughes, MJ, Degen, SJ, Waltz, SE 2001Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasisOncogene20614251PubMed

39.

Lin, HS, Berry, GJ, Fee, WE,Jr, et al. 2004Identification of tyrosine kinases overexpressed in head and neck cancerArch Otolaryngol Head Neck Surg1303116PubMed

40.

Willett, CG, Wang, MH, Emanuel, RL, et al. 1998Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migrationAm J Respir Cell Mol Biol18 48996PubMed

41.

Wang, MH, Kurtz, AL, Chen, Y 2000Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cellsCarcinogenesis21150712PubMed

42.

Zhou, YQ, He, C, Chen, YQ, et al. 2003Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potentialOncogene2218697PubMed

43.

Okino, T, Egami, H, Ohmachi, H, et al. 1999Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosaInt J Oncol1570914PubMed

Titel: RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis
verfasst von: E. Ramsay Camp, MD
Wenbiao Liu, MD
Fan Fan, BS
Anthony Yang, MD
Ray Somcio, BA
Lee M. Ellis, MD
Publikationsdatum: 01.04.2005
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 4/2005
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2005.08.013

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

Nomograms and Staging in Melanoma: New Tools for Better Predicting Outcomes

Results of Hysterectomy in Patients With Bulky Residual Disease at the End of Chemoradiotherapy for Stage IB2/II Cervical Carcinoma

Surgically Resected Hepatocellular Carcinoma: Protean Yet Predictable

Letter to the Editor

Incidence of Unsuspected and Treatable Metastatic Disease Associated With Operable Colorectal Liver Metastases Discovered Only at Laparotomy (and Not Treated When Performing Percutaneous Radiofrequency Ablation)

Prognostic Evaluation of the New American Joint Committee on Cancer/International Union Against Cancer Staging System for Hepatocellular Carcinoma: Analysis of 112 Cirrhotic Patients Resected for Hepatocellular Carcinoma

Update Chirurgie